Clinical trials: Coronary Vasospasm
Endothelial Dysfunction
Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Progenitor Cells and Coronary Atherosclerosis in Humans
AIM III is a prospective, randomized, double-blinded, placebo controlled trial. The study is directly connected to IRB 08-008161 as a specific aim of the National Institute of Health (NIH) grant.
- Trial name
- NCT01067339
- Testing
- darapladib
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Mayo Clinic